Retour sur lavenir.net
   UCB 210.300 € (-0,14 %)     NYXOAH 1.426 € (-4,68 %)     WDP 21.260 € (-1,76 %)     KINEPOLIS GROUP 48.150 € (-0,82 %)     ELIA GROUP 120.400 € (+1,09 %)     CENERGY 23.620 € (+2,87 %)     ASCENCIO 53.300 € (0,00 %)     XIOR 26.100 € (-3,51 %)     DEME GROUP 181.400 € (-0,87 %)     AGEAS 75.750 € (-0,85 %)     JENSEN-GROUP 75.600 € (0,00 %)     AGFA-GEVAERT 0.411 € (-2,38 %)     KBC ANCORA 95.700 € (+0,53 %)     ENERGYVISION 16.920 € (-1,63 %)     EVS 28.900 € (-1,03 %)     TUBIZE-FIN 177.900 € (-0,45 %)     AEDIFICA 67.150 € (-0,44 %)     CMB.TECH 16.800 € (+0,12 %)     DECEUNINCK 2.385 € (0,00 %)     RECTICEL 12.480 € (-3,26 %)     VAN DE VELDE 30.000 € (0,00 %)     BELYSSE GROUP 0.422 € (-7,05 %)     HOME INVEST BE. 18.680 € (-1,89 %)     TITAN S.A. 53.300 € (-1,57 %)     COLRUYT 39.380 € (-0,35 %)     SOFINA 255.600 € (+1,43 %)     D'IETEREN GROUP 176.400 € (-2,22 %)     SHURGARD 22.350 € (-2,61 %)     INCLUSIO SA/NV 16.900 € (+0,60 %)     CIE BOIS SAUVAGE 308.000 € (0,00 %)     SYENSQO 80.350 € (-1,23 %)     FAGRON 21.700 € (+0,23 %)     BEKAERT 38.850 € (-1,40 %)     GIMV 45.600 € (+1,79 %)     RETAIL ESTATES 65.400 € (-1,65 %)     ATENOR 1.150 € (-4,17 %)     AB INBEV 68.020 € (-1,48 %)     ARGENX SE 869.400 € (-2,71 %)     MONTEA 64.700 € (-0,92 %)     SIPEF 105.200 € (+0,96 %)     AZELIS GROUP 12.000 € (-2,52 %)     TINC 11.180 € (-0,53 %)     UMICORE 22.620 € (-1,31 %)     FLUXYS BELGIUM D 22.300 € (-2,19 %)     BARCO 7.995 € (-0,62 %)     PROXIMUS 6.260 € (-1,34 %)     KBC 134.400 € (+0,90 %)     CAMPINE 182.000 € (-1,09 %)     BPOST 1.280 € (-1,08 %)     CARE PROPERTY INV. 12.440 € (-1,43 %)     HYLORIS 4.400 € (-2,00 %)     IMMOBEL 21.000 € (+3,45 %)     NEXTENSA 46.200 € (-1,35 %)     VASTNED 28.500 € (-1,04 %)     MELEXIS 67.850 € (+3,04 %)     SOLVAC NOM(RETAIL) 85.000 € (+0,59 %)     ONTEX GROUP 2.340 € (-4,49 %)     ONWARD MEDICAL 2.500 € (-0,20 %)     WERELDHAVE BELGIUM 51.000 € (+0,79 %)     ORANGE BELGIUM 22.100 € (0,00 %)  
   LISI 61.000 € (+0,33 %)     VALLOUREC 18.865 € (+1,21 %)     MAAT PHARMA 2.880 € (-2,04 %)     TOTALENERGIES 77.300 € (+1,58 %)     WORLDLINE 14.212 € (-2,31 %)     GTT 220.000 € (+1,76 %)     EUROPLASMA 0.001 € (+33,33 %)     ASR NEDERLAND 73.960 € (-0,62 %)     SHOWROOMPRIVE 1.050 € (+9,38 %)     SHELL PLC 40.560 € (+1,13 %)     ARKEMA 59.050 € (-0,42 %)     SARTORIUS STED BIO 186.500 € (-2,00 %)     MERSEN 38.700 € (+2,54 %)     ALSTOM 16.300 € (-1,21 %)     SAINT GOBAIN 74.620 € (-1,53 %)     VINCI 113.600 € (-0,31 %)     EXOSENS 57.450 € (+4,08 %)     MICHELIN 34.470 € (-1,96 %)     BENETEAU 5.690 € (-1,39 %)     SOLUTIONS 30 SE 0.538 € (-0,55 %)     CROSSJECT 1.400 € (+4,48 %)     ADP 108.200 € (-1,10 %)     RIBER 9.480 € (+10,75 %)     ARCADIS 43.980 € (-0,99 %)     ROBERTET 791.000 € (-0,75 %)     BNP PARIBAS ACT.A 104.540 € (0,00 %)     CARREFOUR 16.270 € (-0,82 %)     TETRAGON FIN GRP 14.100 € (+0,71 %)     CRCAM BRIE PIC2CCI 37.200 € (+0,54 %)     AMG 32.660 € (+3,55 %)     KERING 241.400 € (-1,55 %)     CASINO GUICHARD 0.184 € (-0,16 %)     ESSILORLUXOTTICA 148.550 € (-0,83 %)     ACCOR 46.650 € (-0,53 %)     IMERYS 24.660 € (+1,40 %)     PHARMING GROUP 0.982 € (+1,34 %)     ATOS GROUP 26.220 € (-2,24 %)     HAFFNER ENERGY 0.668 € (+12,84 %)     SCHNEIDER ELECTRIC 295.500 € (+2,60 %)     VICAT 65.700 € (+0,31 %)     AKZO NOBEL 60.160 € (-0,95 %)     AHOLD DEL 31.100 € (-1,77 %)     PARROT 9.250 € (-1,28 %)     SPIE 43.780 € (-0,05 %)     ABN AMRO BANK N.V. 43.420 € (+0,67 %)     WINFARM 3.900 € (0,00 %)     WAVESTONE 31.800 € (-1,24 %)     SOITEC 143.350 € (+11,73 %)     ARCELORMITTAL SA 67.540 € (+0,45 %)     SOCIETE GENERALE 75.070 € (+1,20 %)     ALTAREA 88.700 € (-2,53 %)     KAUFMAN ET BROAD 22.550 € (-2,38 %)     ARGAN 72.400 € (-1,76 %)     SANOFI 75.690 € (-0,75 %)     CREDIT AGRICOLE 18.865 € (+0,32 %)     CTP 13.700 € (-1,30 %)     AMOEBA 0.629 € (+0,64 %)     OMER-DECUGIS & CIE 8.400 € (0,00 %)     AXA 44.160 € (-1,08 %)     ASM INTERNATIONAL 862.200 € (+4,48 %)  
News Réglementées
02/09/2026 09:40

Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to participate in trial for innovative mapping and pulsed field ablation system

EQS-News: Texas Cardiac Arrhythmia Institute at St. David's Medical Center / Key word(s): Miscellaneous
Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to participate in trial for innovative mapping and pulsed field ablation system

02.09.2026 / 09:40 CET/CEST
The issuer is solely responsible for the content of this announcement.


AUSTIN, Texas, Sept. 2, 2026 /PRNewswire/ -- The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first facility in the nation to participate in a clinical trial to evaluate the safety and effectiveness of a next-generation mapping and pulsed field ablation system to treat patients with paroxysmal and persistent atrial fibrillation. Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., executive medical director of TCAI and the global principal investigator for the trial, performed the first procedure.

Atrial fibrillation, the most common type of arrhythmia, affects millions of people globally. It occurs when the top two chambers of the heart beat too fast and with an irregular rhythm. Paroxysmal atrial fibrillation is an arrhythmia with symptoms that last for seven days or fewer, while persistent atrial fibrillation is a sustained arrhythmia that lasts for more than a week. Early treatment of paroxysmal and persistent atrial fibrillation can reduce the risk of blood clots, stroke and heart failure—and may prevent the disease from becoming permanent.

"Pulsed field ablation represents one of the most significant advancements in electrophysiology in decades, and this clinical trial will help physicians around the world better understand the safety and effectiveness of this technology," Dr. Natale said. "The Texas Cardiac Arrhythmia Institute remains at the forefront of arrhythmia care, helping to advance technologies that will shape the future of electrophysiology."

The novel catheter system relies on electric fields to ablate targeted heart tissue without using the excess heat or cold used in traditional ablation, helping to reduce the risk of damage to surrounding structures. The system incorporates advanced 3D cardiac mapping technology that provides a detailed view of the heart's electrical activity, enabling physicians to visualize catheter position and tissue contact before and after the energy is delivered. During a traditional ablation procedure, a catheter is guided into the interior of the heart and uses extreme heat or cold to destroy tissue associated with abnormal heart rhythms, creating a greater chance that surrounding structures will be damaged.

TCAI is a state-of-the-art Electrophysiology Center that includes six labs equipped with advanced technology where a group of renowned cardiac electrophysiologists perform a high volume of the most complex electrophysiology procedures.

Cision View original content:https://www.prnewswire.co.uk/news-releases/texas-cardiac-arrhythmia-institute-at-st-davids-medical-center-first-in-us-to-participate-in-trial-for-innovative-mapping-and-pulsed-field-ablation-system-302866616.html

rt.gif?NewsItemId=EN38288B&Transmission_Id=202609020337PR_NEWS_EURO_ND__EN38288B&DateId=20260902


02.09.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2392578  02.09.2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière